文献速递腹部MR

双对比剂肝脏MRI用于肝脏病灶定性

Dual-Contrast Agent Liver MRI for Liver Lesion Characterization.
PubMed 文献 · Radiographics · 2026-01-01

本文阐述细胞外对比剂与肝细胞特异性对比剂在局灶性肝脏病灶评估中的优缺点,提出序贯双对比剂方案(先动态增强细胞外对比剂,再用肝细胞特异性对比剂行肝胆期成像)可兼顾两者优势,适于局灶性肝脏病灶的初始定性。

要点

  • 细胞外对比剂利于显示血管瘤的向心性渐进强化,肝细胞特异性对比剂利于识别含肝细胞病灶并高敏感检出肝细胞缺乏病灶。
  • 单用肝细胞特异性对比剂时,静脉期及移行期强化程度低的血管瘤与转移瘤均呈肝胆期低信号,可能难以鉴别。
  • 双对比剂方案先行动态细胞外对比剂成像、再行肝细胞特异性对比剂肝胆期成像,可提高初始定性的诊断信心与准确度。

核心结论

  • 序贯双对比剂方案兼具细胞外对比剂与肝细胞特异性对比剂的优势,理想适用于局灶性肝脏病灶的初始定性。
  • 作者通过病例示例说明双对比剂技术的优势,使读者能够采用双对比剂肝脏MRI方案以提高初始定性局灶性肝脏病灶的诊断信心与准确度。

研究设计与样本

  • 本文为讲述单对比剂局灶性肝脏病灶成像的利弊、双对比剂成像的原理及双对比剂方案具体细节的综述性文章,并通过病例示例说明双对比剂技术的优势。
  • 原文提及本文补充材料可获取,并附有Welle与Venkatesh的受邀评论。

关键影像表现/征象

  • 细胞外对比剂有助于显示渐进性向心强化,如血管瘤。
  • 肝细胞特异性对比剂有助于识别含肝细胞病灶,如局灶性结节性增生,并对检出肝细胞缺乏病灶如肝转移瘤具有高敏感度。
  • 部分血管瘤在静脉期及移行期强化程度低,且血管瘤与转移瘤在肝胆期均呈低信号,故单用肝细胞特异性对比剂时二者鉴别存在不确定性。
  • 若使用细胞外对比剂,肝腺瘤与局灶性结节性增生的鉴别也可能存在不确定性,需使用肝细胞特异性对比剂随访评估。
  • 肝细胞特异性对比剂可诱发一过性动脉期运动,可能掩盖动脉期高强化。

诊断标准与关键数值

  • 原文未报告敏感度、特异度、AUC、阈值或分级标准的具体数值。
  • 莫迪司(gadobenate)作为混合型对比剂,在动态成像期间表现为细胞外对比剂样行为,但其肝胆期需延迟1小时,且肝胆期常不够稳健。

临床应用与阅片要点

  • 对局灶性肝脏病灶行初始定性时,作者提出可采用序贯双对比剂方案:先以细胞外对比剂行动态成像,再以肝细胞特异性对比剂行肝胆期成像。
  • 使用肝细胞特异性对比剂时需注意其可诱发一过性动脉期运动,可能掩盖动脉期高强化。
  • 使用细胞外对比剂时若肝腺瘤与局灶性结节性增生鉴别不确定,需使用肝细胞特异性对比剂随访评估。
  • 使用莫迪司行肝胆期成像需延迟1小时,且肝胆期常不够稳健。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Focal liver lesion (FLL) evaluation is a common indication for liver MRI. The choice of contrast agent is critical, as extracellular agents (ECAs) and hepatobiliary agents (HBAs [eg, gadoxetate]) have different strengths and weaknesses. ECAs are useful in depicting progressive centripetal enhancement (eg, hemangiomas), whereas HBAs are useful for identifying hepatocyte-containing lesions (eg, focal nodular hyperplasia) and offer high sensitivity for detecting hepatocyte-deficient lesions (eg, hepatic metastases). MRI with HBAs can result in uncertainty in distinguishing hemangiomas from metastases, as some hemangiomas are hypoenhancing at venous and transitional phases and both lesion types are hypointense at the hepatobiliary phase (HBP). There may also be uncertainty in distinguishing between hepatic adenomas and focal nodular hyperplasia if an ECA is used, necessitating a follow-up evaluation with an HBA. Additionally, HBAs can induce transient arterial phase motion, potentially obscuring arterial phase hyperenhancement. Hybrid agent imaging with gadobenate provides ECA-like behavior during dynamic imaging, but the HBP requires a 1-hour delay, often with a less robust HBP. A sequential dual-contrast agent protocol, imaging dynamically with an ECA followed by an HBA for HBP imaging, offers the advantages of both types of agents and is ideally suited for the initial characterization of FLLs. The authors describe the benefits and pitfalls of single-contrast agent FLL imaging, the rationale for dual-contrast agent FLL imaging, and the specifics of a dual-contrast agent protocol. Advantages of a dual-contrast agent technique are illustrated through case examples. The reader will be empowered to adopt a dual-contrast agent liver MRI protocol for greater diagnostic confidence and accuracy in initial FLL characterization. ©RSNA, 2025 Supplemental material is available for this article. See the invited commentary by Welle and Venkatesh in this issue.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Shetty AS, Ludwig DR, Fraum TJ, et al. Dual-Contrast Agent Liver MRI for Liver Lesion Characterization. Radiographics. 2026. PMID: 41411165. doi:10.1148/rg.250113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。